Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.74 |
| ▸ | NPC1 | O15118 | 9/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25335026 | 0.91 | RAB9A (0.61) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL13281549 | 0.88 | RAB9A (0.56) | RAB9ANPC1MAPTTP53LMNA | |
| SCHEMBL20767905 | 0.88 | MAPT (0.67) | RAB9ANPC1MAPTALDH1A1TP53 | |
| SCHEMBL334527 | 0.87 | NPC1 (0.74) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL20767913 | 0.87 | TP53 (0.65) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL31349441 | 0.87 | RAB9A (0.55) | RAB9ANPC1MAPTSMN1; SMN2TP53 | |
| SCHEMBL20767943 | 0.86 | MAPT (0.69) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL26962611 | 0.86 | NPC1 (0.62) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL29858330 | 0.86 | NPC1 (0.62) | RAB9ANPC1MAPTHTTALDH1A1 | |
| SCHEMBL1980790 | 0.85 | NPC1 (0.57) | RAB9ANPC1MAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | Wu, Xiao Hua (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | Wu, Xiao Hua (US) | 2019-03-05 | — | — | US | disclosed |
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2566860-B1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2566860-B1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2566860-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | Bristol-Myers Squibb Company (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
| WO-2011140160-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | GPR119, GPR139, GPR4 | RAB9A 579/4885NPC1 967/4885MAPT 1165/4885 |
| US-10221168-B1 | Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof | MAN2A1, MAN1B1, ALG1 | RAB9A 1295/4885NPC1 1159/4885MAPT 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.